Beyond Air fiscal FY revenue doubles on LungFit PH demand
Beyond Air fiscal FY revenue doubles on LungFit PH demand
Overview
US medical device maker's fiscal 2026 revenue more than doubled, driven by LungFit PH demand
Fiscal 2026 net loss and operating loss missed analyst expectations
Company guides for 15% revenue growth in calendar 2026, over 110% growth in 2027
Outlook
Beyond Air sees calendar 2026 revenue at $8 mln, up 15% from prior year
Company expects 2027 revenue of $16-$18 mln, driven by LungFit PH commercial launch
Beyond Air says expanding market access and international growth support revenue outlook
Result Drivers
LUNGFIT PH DEMAND - Revenue growth was driven by increased demand for LungFit PH in the U.S. and international markets
DISTRIBUTION EXPANSION - Expanded global distribution network for LungFit PH to more than 45 countries, positioning for further international commercial expansion
GROUP PURCHASING AGREEMENT - Awarded a national group purchasing agreement for inhaled nitric oxide therapy with a leading U.S. group purchasing organization, expanding access to healthcare providers
Company press release: ID:nGNX1gdvQN
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
FY EPS |
| -$4.01 |
|
FY Net Income | Miss | -$34.33 mln | -$30.17 mln (3 Analysts) |
FY Operating Income | Miss | -$29.04 mln | -$28.50 mln (3 Analysts) |
FY Gross Profit |
| $252,000 |
|
FY Operating Expenses |
| $29.30 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Beyond Air Inc is $5.00, about 947.6% above its June 25 closing price of $0.48
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on Beyond Air
See all newsBrief: Beyond Air Enters Definitive Agreement To Sell Its NeuroNOS Stake To UNIVO Pharmaceutical Industries In Exchange For Equity And Milestone Payments
Beyond Air Inc reports results for the quarter ended June 30 - Earnings Summary
Beyond Air Q1 net loss slightly widens, reaffirms 2026 outlook
Beyond Air Inc expected to post a loss of $10.80 a share - Earnings Preview
NASDAQ RESUMED AT 04:00 AM